EMEA-001688-PIP03-16 - paediatric investigation plan

Pimavanserin

Key facts

• Active Substance:
  Pimavanserin
• Therapeutic area:
  Psychiatry
• Decision number:
  P/0351/2016
• PIP number:
  EMEA-001688-PIP03-16
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  Treatment of schizophrenia and other psychotic disorders
• Route(s) of administration:
  Oral use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  02/12/2016

Decision

P/0351/2016: EMA decision of 2 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for pimavanserin (EMEA-001688-PIP03-16)

AdoptedReference Number: EMA/765283/2016